Kenvue Inc. $KVUE Shares Sold by Wedmont Private Capital

Wedmont Private Capital lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 14.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,124 shares of the company’s stock after selling 2,265 shares during the quarter. Wedmont Private Capital’s holdings in Kenvue were worth $272,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KVUE. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter valued at approximately $30,000. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in shares of Kenvue in the first quarter valued at approximately $37,000. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich grew its position in shares of Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after purchasing an additional 929 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 1.3%

Shares of NYSE KVUE opened at $18.34 on Monday. The stock has a market cap of $35.20 billion, a P/E ratio of 24.78, a PEG ratio of 2.63 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17. The business’s fifty day simple moving average is $20.87 and its 200-day simple moving average is $22.04.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same period last year, the firm earned $0.32 earnings per share. Kenvue’s quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date was Wednesday, August 13th. Kenvue’s payout ratio is 112.16%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Zacks Research upgraded Kenvue to a “strong sell” rating in a research report on Monday, August 11th. UBS Group lowered their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. JPMorgan Chase & Co. lowered their price objective on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. Citigroup lowered their price objective on Kenvue from $22.00 to $20.00 and set a “neutral” rating for the company in a research report on Tuesday, September 16th. Finally, Evercore ISI lowered their price objective on Kenvue from $25.00 to $23.00 and set an “in-line” rating for the company in a research report on Monday, September 8th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $24.04.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.